Study demonstrates efficacy of treat-to-target in early axial spondyloarthritis

FHS
June 13, 2024
5:00 pm

Early therapeutic interventions in inflammatory rheumatic diseases have proven successful in inducing drug-free remission, and EULAR – The European Alliance of Associations for Rheumatology – recommends early intervention in arthritis, since conventional synthetic disease-modifying antirheumatic drugs (csDMARD) have been shown to slow disease progression in both rheumatoid and psoriatic arthritis.

Contending with Americans’ fury at health insurers

Since last week’s shooting and death of UnitedHealthcare CEO Brian Thompson, there’s been a wave of frustration expressed with the health insurance industry, and support

December 11, 2024

Probiotics for Preterm Infants Could Pose Serious Danger, FDA Warns

The FDA warned the public Thursday that certain probiotic products given to preterm infants in hospital settings are potentially dangerous. The agency also sent warning

October 27, 2023

ALK eyes label expansion after Phase III trial success – Pharmaceutical Technology

ALK plans to seek label expansion to include paediatric patients, with an expected paediatric launch in 2025. Image Credit: Sharomka / Shutterstock. ALK’s Itulatek, a

October 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.